
Pipeline
We are advancing
a robust pipeline
of Supercharged Cell therapies
POWERED BY OUR PROPRIETARY CELL ENHANCEMENTS
Product
Modality
Indications
Discovery
Lead Optimization
PCC
IIT
IND/PH1
CIB-301
LVV
RCC, CRC, NSCLC,
etc.
CIB-350
LVV
B-ALL and auto immunity
CIB-310
LVV
CRC, solid tumors
CIB-380
LVV
MM and auto immunity
CIB-500s
LVV
solid tumors
CIB-600s
LVV
solid tumors
Program stages reflect the latest portfolio overview provided by Cellinfinity.
CLINICAL DEVELOPMENT
Advancing In Vivo CAR-T Cell Therapy into Clinical Evaluation
Cellinfinity Bio is advancing its next-generation in vivo CAR-T cell therapy platform toward clinical evaluation, with a Phase 1 clinical trial registered on ClinicalTrials.gov.
​
The study, titled “CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors,” is designed to evaluate the investigational therapy in patients with advanced malignancies. This open-label, dose-escalation study represents an important step in the clinical development of in vivo CAR-T cell therapy.
Clinical Trial Information
CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors
IDENTIFIER
NCT07657585
STUDY PHASE
Phase 1 (IIT)
STUDY DESIGN
Open-label, dose-escalation
STUDY LOCATION
Beijing, China
STUDY SPONSOR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
COLLABORATOR
Cliniboosta Biotech
